Bone Medical scores in South Korea
Friday, 20 June, 2008
Bone Medical (ASX: BNE) has reached an agreement granting Hyundai Pharmaceuticals a license to sell Bone's osteoperosis products in South Korea.
In exchange for the rights to sell Bone's CaPTHymone oral pathyroid hormone product, Hyundai will pay the company an upfront payment, as well as milestone payments relating to key moments in the product roll-out stage.
Bone will also be eligible for royalties on annual South Korean annual sales of the product.
The formal licensing agreement is yet to be finalised, and the proposed terms of the agreement have not been disclosed by either party.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
